A5049468494- Neuroblastoma Research and Treatments
- Skin Protection and Aging
- Glioma Diagnosis and Treatment
- Indoor Air Quality and Microbial Exposure
- Air Quality and Health Impacts
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Animal and Plant Science Education
- Dermatologic Treatments and Research
- Circular RNAs in diseases
- Cancer survivorship and care
- Urban Green Space and Health
- Ion channel regulation and function
- Science and Education Research
- Ferroptosis and cancer prognosis
- Hospital Admissions and Outcomes
- Colorectal Cancer Screening and Detection
- Global Maternal and Child Health
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Patient-Provider Communication in Healthcare
- Emergency and Acute Care Studies
- Global Health Workforce Issues
- Global Health and Surgery
- Patient Safety and Medication Errors
Levine Children's Hospital
2022-2024
Wayne State University
2022-2023
Helen DeVos Children's Hospital
2020
Corewell Health Blodgett Hospital
2020
Spectrum Health
2020
Children's Hospital of Pittsburgh
2008
University of Pittsburgh
2008
University of Pittsburgh Medical Center
2008
San Diego State University
2000-2006
Graduate School USA
2001
Condition HELP is a unique pediatric patient safety program that gives families an immediate voice in their child's medical care. This endeavor allows parents to call telephone number at any time-24 hours day, 7 days week-if they feel hospitalized health endangered. The receives the same attention as life-threatening emergency, including deployment of specialized rapid response team bedside. article presents 2-year analysis outcomes following implementation program.
Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long-term prognosis for patients with high-risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to phase II trial evaluating DFMO as maintenance therapy HRNB. Event-free survival (EFS) and overall (OS) 81 subjects HRNB treated standard COG induction, consolidation immunotherapy followed by 2 on the NMTRC003/003b Phase were...
Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic transcriptomic profiling tumor samples a molecular board (MTB) approach to make real‑time treatment decisions for children relapsed/refractory tumors. Subjects were divided into three strata: stratum 1-relapsed/refractory neuroblastoma; 2-relapsed/refractory CNS tumors;...
PURPOSE: To explore the rates and correlates of discomfort at mammography in asymptomatic women aged 50–74 years from six San Diego, Calif, facilities. MATERIALS AND METHODS: Subjects (N = 1,800) completed a 43-item telephone interview approximately 3 weeks after screening mammography. Bivariate associations between variables were analyzed with χ2 analysis. Logistic regression was used to assess independent predictors while controlling for all other factors. RESULTS: Nine hundred...
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by "turning off brakes" effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, utility pediatric cancer has not yet been shown to be as fruitful. We review ICIs, use malignancies, and active clinical trials, exemplifying some efforts that could related future trials complications ICI therapy. Through our review, we...
Previous research found that a sun safety program for visitors at 1 zoo increased behaviors. This randomized study compared the effects of tailored dissemination materials plus 2 brief follow-up phone calls (tailored group) versus generic (basic on implementation by other zoos previously evaluated program. Education directors 126 completed surveys several months following initial and year later. During Summer 1, 40% group 24% basic offered least activity (odds ratio=2.2, 95% confidence...
Abstract Children with relapsed/refractory (R/R) neuroblastoma (NB) and medulloblastoma (MB) have poor outcomes. We evaluated the efficacy of nifurtimox (Nfx) in a clinical trial for children R/R NB MB. Subjects were divided into three strata: first relapse NB, multiply All patients received Nfx (30 mg/kg/day TID daily), Topotecan (0.75 mg/m 2 /dose, days 1‐5) Cyclophosphamide (250 every 3 weeks. Response was assessed after two courses using International Neuroblastoma Criteria Evaluation...
Abstract Background Survival for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. Aims To study the feasibility and safety of incorporating a genomic‐based targeted agent to induction therapy HRNB as well adding difluoromethylornithine (DFMO) anti‐GD2 immunotherapy. Methods Twenty newly diagnosed were treated on this multicenter pilot trial. Molecular tumor boards selected one six agents based tumor‐normal whole exome sequencing...
<h3></h3> This paper presents the results of an interim evaluation initiative funded by Tropical Health Education Trust (THET) and hosted Liverpool-Mulago-Partnership. Internationalisation is becoming essential dimension clinical careers resulting in a growth professional volunteering developing countries. The Ugandan Maternal Newborn Hub, formed 2011 seeks to reduce maternal newborn mortality Uganda through improved partnership. In 2012 HUB was awarded funding THET’s Partnership Scheme set...
Abstract High grade gliomas/diffuse midline gliomas (HGG/DMG) historically have a poor prognosis with an overall survival of less than 20% at 5 years. The pathophysiology is under close investigation across the world in efforts to understand this tumor type aims increasing effective treatment options. We present our results on feasibility and outcomes patients treated Molecular Guided Therapy study. Tumor samples were analyzed whole exome (DNA) RNA sequencing. Three drug matching algorithms...